720-777-0123
- Your Visit
-
Research & Innovation
It starts with a Q:
For the latest cutting-edge research, innovative collaborations and remarkable discoveries in child health, read stories from across all our areas of study in Q: Advances and Answers in Pediatric Health.
Elizabeth McFarland, MD
- Medical Director, Children's Hospital Colorado HIV Program
- Infectious Disease - Pediatric
- Pediatrics
Get to know Elizabeth McFarland, MD
- AIDS / HIV Disease
- AIDS Immunization
- Bacterial Infections
- Fungal Infections
- English
I am interested in pediatric infectious diseases, particularly pediatric and perinatal HIV Infection.
Undergraduate 1981
Northwestern University (IL)
Medical Education 1985
Duke University School of Medicine
Internship 1986
University of Colorado (University Hospital) Program
Residency 1988
University of Colorado (University Hospital) Program
Fellowship 1992
University of Colorado (University Hospital) Program
For Patients:
Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.
Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.
For Referring Providers:
Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.
Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.
